Literature DB >> 16771140

[Exclusion of immune proteasomes from mouse ascitic carcinoma Krebs-II cells].

T M Astakhova, N P Sharova.   

Abstract

Pools of 26S and 20S proteasomes were studied in the spleen, liver, lung, and ascitic carcinoma Krebs-II of mouse. Western blotting demonstrated that the pool of 26S proteasomes in ascitic carcinoma Krebs-II was twice that in control lung cells and did not significantly differ by total 26S proteasome quantities from the spleen and liver. At the same time, the level of immune subunit LMP7 was 12 times lower in it compared to lung proteasomes and 4-5 times lower compared to spleen and liver proteasomes. Immune subunit LMP2 was undetectable by this technique in the ascitic carcinoma in contrast to the lung, spleen, and liver. All immune subunits in the studied organs and ascitic carcinoma Krebs-II are components of 26S but not 20S proteasomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16771140

Source DB:  PubMed          Journal:  Izv Akad Nauk Ser Biol        ISSN: 1026-3470


  4 in total

1.  Changes in the activity of proteasomes in vivo induced by oxidative stress or para-aminobenzoic acid in loach embryos.

Authors:  N P Sharova; O G Stroeva; P A Erokhov; S B Dmitrieva; T A Usova
Journal:  Dokl Biochem Biophys       Date:  2007 Jul-Aug       Impact factor: 0.788

2.  Pattern RT1A and proteasome expression in cellular fractions of Zajdela ascitic hepatoma.

Authors:  V I Melnikova; L A Zakharova; I I Khegai; L N Ivanova
Journal:  Dokl Biochem Biophys       Date:  2014-08-30       Impact factor: 0.788

3.  Pattern of proteasome expression in Walker 256 tumor cells after their transplantation into the Brattleboro rats with genetic defect of vasopressin synthesis.

Authors:  N P Sharova; V I Melnikova; I I Khegai; Y D Karpovaa; S B Dmitrieva; T M Astakhova; M A Afanas'eva; N A Popova; L N Ivanova; L A Zakharova
Journal:  Dokl Biochem Biophys       Date:  2008 Mar-Apr       Impact factor: 0.834

4.  Proteasome functioning in breast cancer: connection with clinical-pathological factors.

Authors:  Elena E Shashova; Yulia V Lyupina; Svetlana A Glushchenko; Elena M Slonimskaya; Olga V Savenkova; Alexey M Kulikov; Nikolay G Gornostaev; Irina V Kondakova; Natalia P Sharova
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.